Request Demo

Last update 23 Jan 2025

SERT x DAT x adrenergic receptor x NET

Last update 23 Jan 2025

Basic Info

Related Targets

SERTDATadrenergic receptor[+1]

Drugs associated with SERT x DAT x adrenergic receptor x NET

DOV-102677

Target

DAT x NET x SERT x adrenergic receptor

Mechanism

Dopamine reuptake inhibitors [+3]

Active Org.-

Originator Org.

Euthymics Bioscience, Inc.

Active Indication-

Inactive Indication

Alcoholism [+3]

Drug Highest PhaseDiscontinued

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Tesofensine/Metoprolol Tartrate

Target

DAT x NET x SERT x β-adrenoceptors

Mechanism

DAT antagonists [+3]

Active Org.-

Originator Org.

Saniona AB

Active Indication-

Inactive Indication

Diabetes Mellitus, Type 2 [+2]

Drug Highest PhaseDiscontinued

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with SERT x DAT x adrenergic receptor x NET

EUCTR2021-000127-12-SE

/ Not yet recruitingPhase 2

A Phase 2b, Double-blind, Randomized, Placebo-controlled, Multi center, 16-week Dose finding, Safety and Efficacy Study with Open-label Extension Period of Tesomet in Adult and Adolescent Subjects with Prader-Willi Syndrome

Start Date03 Jan 2022

Sponsor / Collaborator-

NCT05198362

/ WithdrawnPhase 2

A Phase 2b, Double-blind, Randomized, Placebo-controlled, Multi-center, 16-week Dose Finding, Safety and Efficacy Study With Open-label Extension (OLE) Period of Tesomet in Subjects With Prader-Willi Syndrome

This study will evaluate the safety and efficacy of Tesomet (tesofensine + metoprolol) in subjects with PWS.

Start Date28 Dec 2021

Sponsor / Collaborator

Saniona AB

NCT05147415

/ WithdrawnPhase 2

A Phase 2b, Double-blind, Randomized, Placebo-controlled, Dose-finding, Multi-center, 36-week Safety and Efficacy Study With Open-label Extension (OLE) Period of Tesomet in Subjects With Hypothalamic Obesity

This study will evaluate the safety and efficacy of Tesomet (tesofensine + metoprolol) in subjects 18 years of age or older, with HO

Start Date11 Nov 2021

Sponsor / Collaborator

Saniona AB

100 Clinical Results associated with SERT x DAT x adrenergic receptor x NET

100 Translational Medicine associated with SERT x DAT x adrenergic receptor x NET

0 Patents (Medical) associated with SERT x DAT x adrenergic receptor x NET

Literatures (Medical) associated with SERT x DAT x adrenergic receptor x NET

01 Aug 2023·Seminars in Oncology Nursing

Neurotransmitter Gene Polymorphisms Are Associated with Symptom Clusters in Patients Undergoing Radiation Therapy

Article

Author: Oppegaard, Kate ; Cooper, Bruce A ; Levine, Jon D ; Conley, Yvette ; Paul, Steven M ; Calvo-Schimmel, Alejandra ; Morse, Lisa ; Miaskowski, Christine ; Kober, Kord M ; Harris, Carolyn ; Shin, Joosun

OBJECTIVESPurpose was to evaluate for associations between the severity of three distinct symptom clusters (ie, sickness-behavior, mood-cognitive, treatment-related) and polymorphisms for 16 genes involved in catecholaminergic, GABAergic, and serotonergic neurotransmission.DATA SOURCESPatients with breast and prostate cancer (n = 157) completed study questionnaires at the completion of radiation therapy. Memorial Symptom Assessment Scale was used to assess the severity of 32 common symptoms. Three distinct symptom clusters were identified using exploratory factor analysis. Associations between the symptom cluster severity scores and neurotransmitter gene polymorphisms were evaluated using regression analyses.CONCLUSIONSeverity scores for the sickness-behavior symptom cluster were associated with polymorphisms for solute carrier family 6 (SLC6A) member 2 (SLC6A2), SLC6A3, SLC6A1, and 5-hydroxytryptamine receptor (HTR) 2A (HTR2A) genes. For the mood-cognitive symptom cluster, severity scores were associated with polymorphisms for adrenoreceptor alpha 1D, SLC6A2, SLC6A3, SLC6A1, HTR2A, and HTR3A. Severity scores for the treatment-related symptom cluster were associated with polymorphisms for SLC6A2, SLC6A3, catechol-o-methyltransferase, SLC6A1, HTR2A, SLC6A4, and tryptophan hydroxylase 2.IMPLICATIONS FOR NURSING PRACTICEFindings suggest that polymorphisms for several neurotransmitter genes are involved in the severity of sickness-behavior, mood-cognitive, and treatment-related symptom clusters in oncology patients at the completion of radiation therapy. Four genes with various associated polymorphisms were common across the three distinct symptom clusters (ie, SLC6A2, SLC6A3, SLC6A1, HTR2A) which suggest that these clusters have common underlying mechanisms.

01 Jan 2023·Pharmacogenomics

Pharmacogenetics of Anxiety and Depression in Alzheimer’s Disease

Review

Author: Naidoo, Vinogran ; Muñiz, Adriana ; Pego, Rocío ; Carril, Juan C ; Corzo, Lola ; Cacabelos, Ramón ; Martínez-Iglesias, Olaia ; Alcaraz, Margarita ; Cacabelos, Natalia

Anxiety and depression coexist with cognitive impairment in Alzheimer's disease along with other concomitant disorders (>60%), which require multipurpose treatments. Polypharmaceutical regimens cause drug–drug interactions and adverse drug reactions, potentially avoidable in number and severity with the implementation of pharmacogenetic procedures. The accumulation of defective variants (>30 genes per patient in more than 50% of cases) in pharmagenes (pathogenic, mechanistic, metabolic, transporter, pleiotropic) influences the therapeutic response to antidementia, antidepressant and anxiolytic drugs in polyvalent regimens. APOE, CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP4F2, COMT, MAOB, CHAT, GSTP1, NAT2, SLC30A8, SLCO1B1, ADRA2A, ADRB2, BCHE, GABRA1, HMGCR, HTR2C, IFNL3, NBEA, UGT1A1, ABCB1, ABCC2, ABCG2, SLC6A2, SLC6A3, SLC6A4, MTHFR and OPRM1 variants affect anxiety and depression in Alzheimer's disease.

01 Feb 2020·Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan

Mechanism underpinning effects of Shichangpu (Rhizoma Acori Tatarinowii) on attention deficit hyperactivity disorder.

Article

Author: Wang, Junhong ; Chou, Yiqian ; Feng, Kai ; Ren, Xinxin ; Zhao, Ying ; Yu, Qingyang ; Li, Ling

OBJECTIVETo investigate the mechanism underlying the effects of Shichangpu (Rhizoma Acori Tatarinowii) on attention deficit hyperactivity disorder (ADHD).METHODSA network pharmacology approach integrating ingredients of Shichangpu (Rhizoma Acori Tatarinowii) and target with ADHD, network construction, molecular function interactions and pathway analysis was used.RESULTSThis approach successfully helped to identify 7 active ingredients of CN, interacting with 21 key targets (ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, CHRM1, CHRM2, CHRM3, PTGS1, SLC6A2, SLC6A3, SLC6A4, DRD1, DRD5, HTR2A, ADRA1D, MAOB, GRIA2, HTR1A). The molecular function interactions among candidate targets mainly consisted of four groups: G-protein coupled amine receptor activity, catecholamine binding, monoamine transmembrane transporter activity and neurotransmitter receptor activity. Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis indicated that Shichangpu (Rhizoma Acori Tatarinowii)-regulated pathways were mainly classified into signal transduction and monoamine neurotransmitters.CONCLUSIONOur investigation revealed that Shichangpu (Rhizoma Acori Tatarinowii) could improve the symptoms of ADHD by regulating neurotransmitter, in multiple types of compounds-target-pathway, which may be implicated in the major pathological processes of ADHD.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis